Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

phase icon View trials
by phase
cancer type icon View trials by
cancer type
target icon View trials by
therapeutic target
NILEX=new indication line extension; NME=new molecular entity.

phase 3

CLL/SLL
BTK Inhibitor Enrolling
Pirtobrutinib, LOXO-305
MCL
BTK Inhibitor Enrolling
Pirtobrutinib, LOXO-305
Breast Cancer
Abemaciclib, LY2835219
Breast Cancer
Abemaciclib, LY2835219
Breast Cancer
Abemaciclib, LY2835219
Breast Cancer
Abemaciclib, LY2835219
Breast Cancer
Abemaciclib, LY2835219
Medullary Thyroid Cancer
RET Inhibitor Enrolling
Selpercatinib, LOXO-292, LY3527723
NSCLC
RET Inhibitor Enrolling
Selpercatinib, LOXO-292, LY3527723
Gastric Cancer
Ramucirumab, LY3009806, IMC‑1121B
Hepatocellular Carcinoma
Ramucirumab, LY3009806, IMC‑1121B
NSCLC
Ramucirumab, LY3009806, IMC‑1121B